Etwa 500 000 bis 800 000 Menschen sind allein in Deutschland mit dem Hepatitis-C-Virus (HCV) infiziert. Im Mittel 30 Jahre nach der Infektion entwickelt sich eine Leberzirrhose. Die HCV-Genotypen haben nach überwiegender Einschätzung keinen Einfluss auf den natürlichen Verlauf der Erkrankung. Für Patienten mit einer HCV-assoziierten Leberzirrhose ist das Risiko der Entwicklung eines hepatozellulären Karzinoms (HCC) deutlich erhöht (2 - 5 % pro Jahr).
Literatur
1
Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Pape G, Hopf U, Zeuzem S.
Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial.
J Hepatol.
2002;
36
(Suppl)
3
4
Hadziyannis S J, Cheinquer H, Morgan T, Diago M, Jensen D M, Sette H, Ramadori G, Bodenheimer H C, Marcellin P, Lee S -D, Roberts P J, Ackrill A M.
Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose.
J Hepatol.
2002;
36
(Suppl 1)
3
6
Lindsay K L, Trepo C, Heintges T, Shiffman M L, Gordon S C, Hoefs J C, Schiff E R, Goodman Z D, Laughlin M, Yao R, Albrecht J K.
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Hepatology.
2001;
34
395-403
7
Manns M P, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M, Albrecht J K.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet.
2001;
358
958-65
8
McHutchison J G, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K, Goodman Z D, Ling M H, Cort S, Albrecht J K.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med.
1998;
339
1485-1492
10
Poynard T, Marcellin P, Lee S S, Niederau C, Minuk G S, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J.
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet.
1998;
352
1426-1432
11
Reddy K R, Wright T L, Pockros P J. et al .
Efficacy and safety of pegylated (40 kd) interferon alfa-2a compared with interferon alfa-2a in noncirrhotic patients with chronic hepatitis C.
Hepatology.
2001;
33
433-438
12
Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T.
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view.
Gastroenterology.
1999;
116
378-386
13
Xu Z X, Patel I, Joubert P.
Single-dose safety/tolerability and pharmacokinetics/ pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon alfa-2a (IFN alfa-2a) to healthy subjects.
Hepatology.
1998;
28
(Suppl)
702
14
Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Inhibition of hepatocarcinogenesis by interferon therapy.
Ann Intern Med.
1999;
131
174-181
16
Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda M J.
Peginterferon alfa-2a in patients with chronic hepatitis C.
N Engl J Med.
2000;
343
1666-1672
17
Zeuzem S, Herrmann E, Lee J H, Fricke J, Neumann A U, Modi M, Colucci G, Roth W K.
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.
Gastroenterology.
2001;
120
1438-1447
